Is Diamondback Energy a Good Stock to Buy?
Diamondback Energy (FANG) is a lesser-known diamond in the rough…
Sell
25
IRON Quote, Financials, Valuation and Earnings
Last price:
$52.50
Seasonality move
:
12.97%
Day range:
$51.57 - $53.60
52-week range:
$25.60 - $68.73
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
4.11x
Volume:
182.2K
Avg. volume:
342.7K
1-year change:
-11.28%
Market cap:
$1.8B
Revenue:
--
EPS (TTM):
-$3.99
Analysts' Opinion
-
Consensus RatingDisc Medicine has received a consensus rating of Buy. The company's average rating is a Buy based on 8 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $97.82, Disc Medicine has an estimated upside of 85.3% from its current price of $52.79.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $75.00 representing 100% downside risk from its current price of $52.79.
Fair Value
-
According to the consensus of 8 analysts, Disc Medicine has 85.3% upside to fair value with a price target of $97.82 per share.
IRON vs. S&P 500
-
Over the past 5 trading days, Disc Medicine has underperformed the S&P 500 by -2.04% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Disc Medicine does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Disc Medicine has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Disc Medicine reported revenues of --.
Earnings Growth
-
Disc Medicine has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Disc Medicine reported earnings per share of -$0.98.
Enterprise value:
1.4B
EV / Invested capital:
--
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
--
EV / Free cash flow:
-14.44x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
--
Net Income Margin (TTM):
--
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -$47.5M | -$91.1M | -$129.7M | -$29.7M | -$34.6M | |
| EBITDA | -$47.4M | -$76.2M | -$108.3M | -$14.9M | -$13.3M | |
| Diluted EPS | -$44.95 | -$3.49 | -$3.99 | -$0.97 | -$0.98 | |
| Period Ending | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | -- | $90.5M | $198.5M | $365.7M | $493.6M | |
| Total Assets | -- | $92.4M | $200.2M | $368M | $496.8M | |
| Current Liabilities | -- | $13.4M | $22.6M | $21.4M | $23.3M | |
| Total Liabilities | -- | $156.6M | $23.6M | $22.9M | $53.2M | |
| Total Equity | -- | -$64.2M | $176.6M | $345.1M | $443.6M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$42.3M | -$73.5M | -$93.9M | -$17.8M | -$27.6M | |
| Cash From Investing | -$151K | -$89K | -$292.3M | -$3K | -$1.4M | |
| Cash From Financing | $149M | $239.4M | $218.3M | $7.8M | $28.8M | |
| Free Cash Flow | -$42.4M | -$73.6M | -$94.4M | -$17.8M | -$28M | |
IRON
Sector
Market Cap
$1.8B
$39.2M
Price % of 52-Week High
76.81%
45.99%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.81%
1-Year Price Total Return
-11.28%
-38.63%
Beta (5-Year)
--
0.774
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$52.60
200-day SMA
Buy
Level
$52.39
Bollinger Bands (100)
Sell
Level
52.93 - 63.91
Chaikin Money Flow
Sell
Level
-15.9M
20-day SMA
Sell
Level
$53.87
Relative Strength Index (RSI14)
Sell
Level
45.06
ADX Line
Sell
Level
12.73
Williams %R
Neutral
Level
-66.0522
50-day SMA
Sell
Level
$55.42
MACD (12, 26)
Sell
Level
-0.81
25-day Aroon Oscillator
Sell
Level
-32
On Balance Volume
Neutral
Level
26.8M
Financial Scores
--
Altman Z-Score
(Annual)
Level (--)
--
CA Score
(Annual)
Level (--)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (3)
--
Ohlson Score
Level (--)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Disc Medicine Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for hematologic diseases. It aims to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for erythropoietic porphyrias (EPs) including erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF) and anemia of chronic kidney disease (CKD); and DISC-3405 for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, the Company’s preclinical programs include DISC-0998.
Stock Forecast FAQ
In the current month, IRON has received 8 Buy ratings 0 Hold ratings, and 0 Sell ratings. The IRON average analyst price target in the past 3 months is $97.82.
-
Where Will Disc Medicine Stock Be In 1 Year?
According to analysts, the consensus estimate is that Disc Medicine share price will rise to $97.82 per share over the next 12 months.
-
What Do Analysts Say About Disc Medicine?
Analysts are divided on their view about Disc Medicine share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Disc Medicine is a Sell and believe this share price will drop from its current level to $75.00.
-
What Is Disc Medicine's Price Target?
The price target for Disc Medicine over the next 1-year time period is forecast to be $97.82 according to 8 Wall Street analysts, 8 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is IRON A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Disc Medicine is a Buy. 8 of 8 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of IRON?
You can purchase shares of Disc Medicine via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Disc Medicine shares.
-
What Is The Disc Medicine Share Price Today?
Disc Medicine was last trading at $52.50 per share. This represents the most recent stock quote for Disc Medicine. Yesterday, Disc Medicine closed at $52.79 per share.
-
How To Buy Disc Medicine Stock Online?
In order to purchase Disc Medicine stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
What Is Hindsight Bias In Investing?
You’ve probably heard the expression “hindsight is 20/20.” That saying…
Is Rivian a Good Stock a Buy?
Rivian Automotive (RIVN) had an initial IPO of close to…
Stock Ideas
Buy
58
Is AAPL Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 37x
Buy
52
Is NVDA Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 41x
Buy
53
Is MSFT Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 33x
Alerts
Sell
29
UNF alert for Mar 26
UniFirst [UNF] is up 0.24% over the past day.
Sell
30
KEQU alert for Mar 26
Kewaunee Scientific [KEQU] is down 1.45% over the past day.
Buy
82
EPAC alert for Mar 26
Enerpac Tool Group [EPAC] is down 3.19% over the past day.
